MannKind Corporation (MNKD)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 65 | 75 | 100 | 199 | 286 | 349 | 394 | 443 |
| Operating profit | $m | 39 | - | ||||||
| Net profit | $m | -57 | -81 | -87 | -12 | 28 | 6 | -44 | -58 |
| EPS reported | $ | 0.02 | -0.14 | ||||||
| Operating cashflow per share | $ | 0.06 | -0.03 | ||||||
| Capex per share | $ | 0.01 | 0.03 | ||||||
| FCF per share | $ | 0.04 | -0.06 | ||||||
| Free cash flow | $m | 14 | -19 | ||||||
| Net debt | $m | 198 | 210 | ||||||
| Book value equity | $m | -51 | -67 | ||||||
| Book value per share | $ | -0.16 | -0.22 | ||||||
| Number of shares | m | 314.11 | 309.19 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 283.50 | - | ||||||
| P/B LTM | x | -33.97 | -25.79 | ||||||
| P/S LTM | x | 4.97 | 4.40 | ||||||
| P/FCF LTM | x | 126.60 | -93.33 | ||||||
| EV/EBITDA LTM | x | 77.45 | 69.33 | ||||||
| EV/Sales LTM | x | 6.11 | 3.83 | ||||||
| Earnings Yield LTM | % | +0.35% | -3.66% | ||||||
| FCF Yield | % | +0.79% | -1.07% | ||||||
| Quality | |||||||||
| ROE | % | -11.49% | +78.60% | ||||||
| ROIC | % | +5.79% | +1.18% | ||||||
| Operating margin | % | +11.12% | +1.97% | ||||||
| Gross margin | % | +82.47% | +75.69% | ||||||
| FCF/Sales | % | +3.92% | -4.72% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | -79.42% | - | ||||||
| Sales Growth YoY | % | +22.23% | +37.87% | ||||||
| Net Income Growth YoY | % | -78.75% | - | ||||||
| FCF Growth | % | -58.29% | - | ||||||
| Operating Profit Growth | % | -46.55% | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | 0.03 | -0.06 | ||||||
| Net Debt/EBITDA | x | 14.48 | 9.04 | ||||||
| EBIT/Net interest | x | 2.81 | 0.17 | ||||||
| Net debt/market cap | % | +21.33% | +25.95% | ||||||
| Net debt/Equity | x | -3.89 | -3.13 | ||||||
| Gross debt/equity | x | -9.28 | -4.92 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
MannKind Corporation operates as a biopharmaceutical firm, primarily focused on innovating and bringing to market respiratory-delivered treatments. Its efforts are directed towards tackling endocrine system disorders and rare lung conditions within the U.S. market. The company's key product is Afrezza, an inhaled insulin designed to improve glycemic control for adults managing diabetes. MannKind also actively markets Thyquidity, promoting it to adult and pediatric endocrinologists and other healthcare professionals for the treatment of hypothyroidism. In terms of collaborations, MannKind holds a strategic licensing and partnership agreement with United Therapeutics Corporation. Furthermore, it is collaborating with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), which is a synthetic variant of human vasoactive intestinal peptide intended to shield cells from inflammatory processes. Established in 1991, MannKind Corporation's corporate offices are located in Westlake Village, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
MannKind Corporation operates as a biopharmaceutical firm, primarily focused on innovating and bringing to market respiratory-delivered treatments. Its efforts are directed towards tackling endocrine system disorders and rare lung conditions within the U.S. market. The company's key product is Afrezza, an inhaled insulin designed to improve glycemic control for adults managing diabetes. MannKind also actively markets Thyquidity, promoting it to adult and pediatric endocrinologists and other healthcare professionals for the treatment of hypothyroidism. In terms of collaborations, MannKind holds a strategic licensing and partnership agreement with United Therapeutics Corporation. Furthermore, it is collaborating with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), which is a synthetic variant of human vasoactive intestinal peptide intended to shield cells from inflammatory processes. Established in 1991, MannKind Corporation's corporate offices are located in Westlake Village, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free